Effects Of Donepezil Treatment On Mild To Moderate Alzheimer Disease And Serum Level Of Inflammatory Factor

Objective:To explore the effects of Donepezil treatment on mild to moderate Alzheimer’s disease (AD) and serum level of Inflammatory cytokines.Methods:The36cases of mild to moderate AD patient group were given Donepezil (5mg,1times/day) for24weeks. The neuropsychological scores of MMSE, ADAS-Cog and ADAS-ADL were performed before therapy treatment, the12th week and24th week after treatment. Detected the IL-1β, IL-6, TNF-a levels in the patient group before and after treatment Donepezil by enzyme-linked immunosorbent assay (ELIS A), and compared with the normal controls.Result:①Before treatment, the IL-1β, IL-6and TNF-α levels in patients’serum were significantly higher than after treatment and the control group (P<0.05)②AD patients after Donepezil treatment, the MMSE score, ADAS-ADL scores were significantly higher than before treatment, ADAS-Cog scores were significantly lower than before treatment (P<0.05-0.005); ③The aspects of memory and word recall test, structured exercises and word to identify of ADAS-Cog has improved significantly than before treatment, and the difference was statistically significant (P<0.05-0.001)④Before treatment, the IL-1β, IL-6and TNF-α levels in patients’serum were significantly higher than the control group (P<0.01), after24weeks treatment, the levels of inflammatory cytokines was significantly lower than before treatment (P<0.05-0.001);⑤The inflammatory factor levels in serum of the patient group before Donepezil treatment had a significant negative correlation with the MMSE score, ADAS-ADL score (P<0.01), while having positive correlation with the ADAS-Cog score (P<0.05-0.01)Conclusion:Donepezil can improve cognitive function and activities of daily living, especially memory and visuospatial ability of mild to moderate AD patients, and can inhibit the expression of inflammatory cytokines, reduced the serum levels of inflammatory cytokines.